Alexandra Rojek, MD is a hematologist/oncologist specializing in the care of adults with lymphoma and has a particular interest in the use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of lymphoma patients. She has expertise in the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma, T cell lymphomas, and the role of stem cell transplantation in the treatment of different lymphomas in addition to CAR T cell therapy. Dr. Rojek’s laboratory research focuses on identifying immunology mechanisms underlying the success of cellular therapies and developing strategies to leverage these mechanisms to improve cellular therapy efficacy for patients. Her research aims to then translate these findings into early phase trials utilizing cellular therapies for patients with lymphoma as well as other malignancies.
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study. Am J Hematol. 2025 Jun; 100(6):1082-1085.
PMID: 40062542
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia.
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia. EJHaem. 2024 Aug; 5(4):728-737.
PMID: 39157611
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531.
PMID: 38701405
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024 08; 99(8):1624-1627.
PMID: 38769663
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
PMID: 37827881
Residency Training in the COVID-19 Pandemic-Addressing the Need for Systems-Based Education.
Residency Training in the COVID-19 Pandemic-Addressing the Need for Systems-Based Education. JAMA Health Forum. 2022 09 02; 3(9):e223023.
PMID: 36218931
Analysis of Narrative Text in Evaluations of Continuing Medical Education Faculty by Gender.
Analysis of Narrative Text in Evaluations of Continuing Medical Education Faculty by Gender. JAMA Netw Open. 2022 08 01; 5(8):e2227948.
PMID: 35994291
Residents as Innovators on COVID-19 Respiratory Isolation Units.
Residents as Innovators on COVID-19 Respiratory Isolation Units. Acad Med. 2022 07 01; 97(7):946-947.
PMID: 34554949
Evolution of therapy for limited stage diffuse large B-cell lymphoma.
Evolution of therapy for limited stage diffuse large B-cell lymphoma. Blood Cancer J. 2022 02 24; 12(2):33.
PMID: 35210407